Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility

American Journal of Human Genetics

Volumn 72, Issue 4, 2003, Pages 1023-1028

  Schutte, Mieke ^a   Seal, Sheila ^b   Barfoot, Rita ^b   Meijers Heijboer, Hanne ^a   Wasielewski, Marijke ^a   Evans, D Gareth ^c   Eccles, Diana ^d   Meijers, Carel ^a   Lohman, Frans ^a   Klijn, Jan ^a   Van Den Ouweland, Ans ^a   Futreal, P Andrew ^e   Nathanson, Katherine L ^f   Weber, Barbara L ^f   Easton, Douglas F ^g   Stratton, Michael R ^b,e   Rahman, Nazneen ^b   Brady, A ^h   Cole, T ^h   Collins, A ^h   Cox, H ^h   Donaldson, A ^h   Eeles, R ^h   Gregory, H ^h   Gray, J ^h   Houlston, R ^h   Lalloo, F ^h   Lucassen, A ^h   Mackay, J ^h   Mitchell, G ^h   Morrison, P ^h   Murday, V ^h   Narod, S ^h   Patterson, J ^h   Peretz, T ^h   Phelan, C M ^h   Rogers, M ^h   Schofield, A ^h   Tonin, P ^h   Weber, W ^h   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

^d PRINCESS ANNE HOSPITAL   (United Kingdom)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^f HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ALLELE; ARTICLE; BREAST CARCINOMA; CANCER FAMILY; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; GENETIC SCREENING; GENETIC VARIABILITY; GERM LINE; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; NORTH AMERICA; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0345669750     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/373965     Document Type: Article

References (27)

1. Allinen M, Huusko P, Mäntyniemi S, Launonen V, Winqvist R (2001) Mutation analysis of the CHK2 gene in families with hereditary breast cancer. Br J Cancer 85:209-212
2. Bartek J, Falck J, Lukas J (2001) CHK2 kinase: a busy messenger. Nat Rev Mol Cell Biol 2:877-886
3. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528-2531
4. Bougeard G, Limacher JM, Martin C, Charbonnier F, Killian A, Delattre O, Longy M, Jonveaux P, Fricker JP, Stoppa-Lyonnet D, Flaman JM, Frebourg T (2001) Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. J Med Genet 38:253-257
5. Chase DS, Tawn EJ, Parker L, Jonas P, Parker CO, Burn J (1998) The North Cumbria Community Genetics Project. J Med Genet 35:413-416
6. Chehab NH, Malikzay A, Appel M, Halazonetis TD (2000) Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 14:278-288
7. The CHEK2-Breast Cancer Consortium (2002) Low-penetrance susceptibility to breast cancer due to CHEK2* 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55-59
8. Durocher D, Taylor IA, Sarbassova D, Haire LF, Westcott SL, Jackson SP, Smerdon SJ, Yaffe MB (2000) The molecular basis of FHA domain: phosphopeptide binding specificity and implications for phospho-dependent signaling mechanisms. Mol Cell 6:1169-1182
9. Falck J, Mailand N, Syljusen RG, Bartek J, Lukas J (2001) The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410:842-847
10. Ganguly A, Rock MJ, Prockop DJ (1993) Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments. Proc Natl Acad Sci USA 90:10325-10329
11. Hofmann WK, Miller CW, Tsukasaki K, Tavor S, Ikezoe T, Hoelzer D, Takeuchi S, Koefller HP (2001) Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukaemia. Leuk Res 25:333-338
12. Ingvarsson S, Sigbjornsdottir BI, Huiping C, Hafsteinsdottir SH, Ragnarsson G, Barkardottir RB, Arason A, Egilsson V, Bergthorsson JT (2002) Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res 4:R4
13. Lee JS, Collins KM, Brown AL, Lee C-H, Chung JH (2000) hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404:201-204
14. Lee SB, Kim SH, Bell DW, Wahrer DC, Schiripo TA, Jorczak MM, Sgroi DC, Garber JE, Li FP, Nichols KE, Varley JM, Godwin AK, Shannon KM, Harlow E, Haber DA (2001) Destabilisation of CHK2 by a missense mutation associated with Li-Fraumeni syndrome. Cancer Res 61:8062-8067
15. Li J, Williams BL, Haire LF, Goldberg M, Wilker E, Durocher D, Yaffe MB, Jackson SP, Smerdon SJ (2002) Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell 9:1045-1054
16. Matsuoka S, Huang M, Elledge SJ (1998) Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282:1893-1897
17. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ (2000) Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 97:10389-10394
18. Petrij-Bosch A, Peelen T, van Vliet M, van Ejik R, Olmer R, Drusedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers-Heijboer H, Klijn JG, Vasen HF, Cornelisse CJ, van't Veer LJ, Bakker E, van Ommen GJ, Devilee P (1997) BRCA1 genomic deletions are major founders in Dutch breast cancer patients. Nat Genet 17:341-345
19. Reddy A, Yuille M, Sullivan A, Repellin C, Bell A, Tidy JA, Evans DJ, Farrell PJ, Gusterson B, Gasco M, Crook T (2002) Analysis of CHK2 in vulval neoplasia. Br J Cancer 86:756-760
20. Sodha N, Houlston RS, Williams R, Yuille MA, Mangion J, Eeles RA (2002) A robust method for detecting CHK2/RAD53 mutations in genomic DNA. Hum Mutat 19:173-177
21. Sullivan A, Yuille M, Repellin C, Reddy A, Reelfs O, Bell A, Dunne B, Gusterson BA, Osin P, Farrell PJ, Yulug I, Evans A, Ozcelik T, Gasco M, Crook T (2002) Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene 21:1316-1324
22. Vahteristo P, Bartkova J, Eerola H, Syrjäkoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomäki K, Heikkilä P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H (2002) A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71:432-438
23. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K, Nevanlinna H (2001) p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni Syndrome. Cancer Res 61:5718-5722
24. Wu X, Webster SR, Chen J (2001) Characterization of tumor-associated Chk2 mutations. J Biol Chem 276:2971-2974
25. Xu X, Tsvetkov LM, Stern DF (2002) Chk2 activation and phosphorylation-dependent oligomerisation. Mol Cell Biol 22:4419-4432
26. Zeng Y, Forbes KC, Wu Z, Moreno S, Piwnia-Worms H, Enoch T (1998) Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1. Nature 395:507-510
27. Zhou BB and Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408:433-349